MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company’s full financial results for the fourth quarter and the fiscal year... Read more
MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both effective as of January 8, 2021. “I am delighted to have Mark... Read more
MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both effective as of January 8, 2021. Read more
MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both effective as of January 8, 2021. “I am delighted to have Mark... Read more
MENLO PARK, Calif ., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for... Read more
MENLO PARK, Calif ., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for... Read more
MENLO PARK, Calif ., Jan. 08, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for... Read more
Venlo, the Netherlands, January 8, 2021 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. He will also become a member of the Audit Committee. Dr. Haag was chosen as part of an expansion process launched by the... Read more
WASHINGTON, Jan. 7, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2020 on Thursday, January 28, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour. The call and an accompanying slide presentation will be webcast on the “Investors” section of Danaher’s... Read more
WASHINGTON, Dec. 21, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today that Jose-Carlos (“JC”) Gutierrez-Ramos has been named Senior Vice President and Chief Scientific Officer for Danaher. In this role, Dr. Gutierrez-Ramos will have responsibility for helping define Danaher’s science and technology strategy across the organization, including facilitating innovation and further development of scientific and... Read more